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Introduction
Injecting drug users (IDUs) are at high risk from hepatitis B due to sharing of injection
equipment and through sexual spread. It is estimated that 21% of injecting drug users in
England and Wales have evidence of past or current hepatitis B infection.1  Hepatitis B
disease can be prevented by vaccination. IDUs have been targeted since 1988 for
vaccination. Despite this, both availability of vaccination and uptake by IDUs are recognised
to be poor in the UK.2, 3  Proactive provision of hepatitis B vaccination through widely
available services is critical for protecting this difficult to reach target group.
Practices who opt to provide a National Enhanced Service to patients with drug misuse problems under the
new GMS contract will be expected to undertake six-monthly audits of hepatitis B screening and immunisation
data of this patient population (http://www.doh.gov.uk/gmscontract/nesdrug.pdf). This paper contains
guidance on how screening and immunisation should be carried out and suggests criteria to facilitate audits.
Availability and accessibility
Hepatitis B vaccination should be considered an essential
component of the care offered to drug users in primary
care. Poor patient attendance is often reported as a
major barrier. To address this issue, vaccination needs
to be carried out opportunistically at the time when the
drug user makes contact with the practice, e.g. at the
time of methadone prescribing. Practices should keep
a stock of hepatitis B vaccine.
Pre-vaccination testing
It has been standard practice to advise that clinicians
wait for hepatitis B test results before giving the first dose
of vaccine. The rationale for this advice was to prevent
unnecessary vaccination of those who have already been
infected or previously vaccinated. Due to poor uptake of
vaccination, current expert advice is to focus on protection
through vaccination rather than testing. The Department
of Health has dispensed with routine pre-vaccination
testing in the national hepatitis B immunisation programme
for prisons.4
Pre-testing should never act as a barrier or delay to
vaccination. Drug users should have access to vaccination
without testing if desired. If a drug user wishes to be
tested, the first dose of vaccine should be offered at the
same time.2, 5   Delaying vaccination can do harm because
a drug user may become infected before the next visit
or may not return.2
The aims of testing need to be considered to ensure
that it is of benefit. Testing for hepatitis B surface antigen
(HBsAg) is worthwhile if those found to be positive are
followed up in primary care with advice about prevention
of transmission and contact tracing for vaccination.2
All HBsAg positive patients should be offered referral to
a specialist (hepatologist, infectious diseases physician
or gastroenterologist) for further assessment.
The patient is less likely to benefit from testing for antibody
to hepatitis B core antigen (anti-HBc). A positive result
indicates present or past hepatitis B infection. Current
advice is that further hepatitis B vaccination is not
necessary if positive.2
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Primary vaccination schedule
A pragmatic approach to vaccination schedule is
recommended. Every time a drug user contacts the
practice, the healthcare worker should consider whether
hepatitis B vaccination should be offered. Emphasis
needs to be placed on giving as many doses as possible.
Lack of certainty of vaccination status should not act as
a barrier to vaccination and reliance on recall of history
of vaccination is not advised.
 Accelerated schedules (0, 1 and 2 months or 0, 7
and 21 days) are now widely recognised as the most
appropriate for people at high risk including drug users.
A study of homeless drug users at an inner city primary
care centre found a seven times higher completion
rate with the 0, 7 and 21 day schedule compared
with the conventional 6 month schedule.7  The 0, 7 
and 21 day schedule is being promoted by the
Department of Health for prisons.4
 Even incomplete vaccination schedules offer
some protection.6
 In addition services need to ensure that there is a
robust system for recall.
Booster doses
Current best practice is to give a booster at 12 months
if an accelerated schedule is used.8  Again, a flexible
pragmatic approach is advisable for IDUs who are often
not in sustained contact with services. When a drug user
presents to services, the healthcare worker should
consider whether this is an opportune time to offer a
booster dose.
Post-vaccination testing
An alternative approach is to test for antibodies to the
hepatitis B surface antigen (anti-HBs) at least 1 month
after the primary course and make a decision about
whether a booster dose is needed depending on the
antibody levels (table 1).9  Routine post-vaccination
testing is not recommended for drug users as a group
because of the practical difficulties with follow-up.9
5–10% of healthy people will not mount an effective
antibody response after vaccination.10  Some of these
apparent non-responders may still be protected against
clinically significant infection.9  People with an immune
disorder, e.g. due to HIV infection, are at higher risk of
failing to respond and may need regular testing for
anti-HBs and a booster injection when the level falls
below 10mIU/ml.9
Promotion of vaccination
Prominent display of posters and use of leaflets promoting
hepatitis B vaccination may be helpful. Promotion of
vaccination is dependent on motivated knowledgeable
staff. In drug services, uptake rates have been found
to be higher where staff training and confidence
were better.12 GPs and practice nurses may also
need training and awareness sessions to ensure
greater uptake of vaccination.
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Vaccination of partners and children
of drug users
The partners and children of drug users are also at risk
of hepatitis B infection but their need for vaccination is
often overlooked. Hepatitis B can be transmitted through
sexual contact and non-sexual intimate contact.
Children infected with hepatitis B have a higher risk
of chronic infection than adults.
Organising the vaccination of families may not be
straightforward. Families may not be registered with
the same practice as the drug user. Some drug users
may be reluctant to disclose the risk to their partners.
Healthcare workers need to work with drug users to
advise them of the risks and promote the routine
offering of vaccination to partners and children.
Hepatitis A vaccination
IDUs are at higher risk of hepatitis A infection due to poor
living conditions with spread probably occurring through
faecal contamination of drugs or injecting paraphernalia.13
Blood to blood spread through needle sharing during
viraemia is also possible.
Hepatitis A vaccination of IDUs infected with hepatitis C
and / or with chronic liver disease has been recommended
for many years because of the risk of more serious illness
if they became infected.11  The Public Health Laboratory
Service Advisory Committee on Vaccination and
Immunisation expanded this recommendation in 2001
to include all IDUs.14
As for hepatitis B, it is advisable to offer drug users a
hepatitis A vaccine without pre-testing because of the
risk that the opportunity to vaccinate may be lost,
e.g. due to the drug user not returning.14
Hepatitis A vaccine is available as a single component
vaccine or combined with hepatitis B vaccine (table 2).
The likelihood of a drug user returning for a subsequent
dose needs to be taken into account when selecting the
single vaccine or the combined vaccine. One dose of
hepatitis A vaccine confers greater protection against
hepatitis A than one dose of the combined vaccine
because the combined vaccine only has half the amount
of hepatitis A antigen than the single component vaccine.
Monitoring
Local information on vaccine uptake and completion is
crucial in order to judge the quality of the service and
plan achievable improvements. The minimum information
required is the number of vaccinations received by a
drug user.15 An easy recording system is needed.
Suggested criteria for audit
Criteria for audit should be kept simple.
The minimum criteria should be:
 The number and percentage of drug users who
have received 1 dose of hepatitis B vaccine (HBV).
 The number and percentage of drug users who
have received 2 doses of HBV.
 The number and percentage of drug users who
have received 3 doses of HBV.
Other criteria to consider include:
 The number and percentage of drug users who
have been offered hepatitis B vaccination.
 The percentages of drug users who have received
1 and 2 doses of hepatitis A vaccine.
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Table 1: Post vaccination antibody testing and actions to consider 9,10,11
Antibody level (miu/ml) Status Action
<10 Non-response Screen for markers of present or past infection
(HbsAg, antiHBc). Give additional dose.
Consider repeating full course.
10–100 Poor response Give additional dose.
>100 Protective No further action needed if immunocompetent.
Table 2: Recommended schedules of hepatitis A and B vaccines 8
Hepatitis Vaccines Schedule
Single A 2 doses with second dose after 6–12 months.
Second dose may be delayed for up to 3 years.
Combined A and B Routine: 0, 1, 6 months.
Accelerated: 0, 7, 21 days with booster ideally at 12 months.
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Summary of recommendations
 Vaccinate all drug users against hepatitis B (non-injectors may become injectors).
 No need to carry out pre-vaccination testing.
 Use accelerated 0, 7 and 21 day schedule.
 Offer hepatitis B vaccination to partners and children.
 Vaccinate all injecting drug users against hepatitis A.
 Single component hepatitis A vaccine preferable to combined hepatitis A and B vaccine.
 Devise and use an easy recording system to enable audit.
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